Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).

Abstract: A method for separating oil-water two-phase NMR signals by using dynamic nuclear polarization comprising: using a combination of a non-selective free radical and a selective relaxation reagent to selectively enhance an NMR signal of an oil phase or a water phase, the relaxation reagent being capable of selectively suppressing dynamic polarization enhancement of the water phase or oil phase, thus achieving the polarization enhancement of a single fluid phase in the mixed fluid phases and realizing separation of the two-phase signals; or using a selective free radical to selectively enhance the NMR signal of the oil phase or the water phase, thus achieving the polarization enhancement of a single fluid phase in the mixed fluid phases and realizing separation of the oil-water two-phase NMR signals. The method is simple and easy to operate, has a short test time, and can efficiently separate NMR signals of oil and water phases.

Abstract: Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor in combination with immune checkpoint inhibitors in mammals with cancer.

Abstract: Cocrystals of an adenosine A2B receptor antagonist, 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-3,7-dihydro-1H-purine-2,6-dione, methods of preparing the cocrystals, pharmaceutical compositions of the cocrystals, and uses of the cocrystals are disclosed.

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the monocarboxylic acid transporter 4 (MCT4) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of monocarboxylic acid transporter 4 (MCT4) or that we benefit from modulating the monocarboxylic acid transporter 4 (MCT4).

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the A2A adenosine receptor with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the A2A adenosine receptor, such as cancer, with A2A adenosine receptor antagonists.

Abstract: Disclosed herein are compounds, compositions, and methods for modulating the prostaglandin E2 receptor 4 (EP4) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the action of prostaglandin E2 (PGE2) at the prostaglandin E2 receptor 4 (EP4), such as cancer, with EP4 antagonists.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor.

Abstract: Disclosed herein are compounds of Formula (III), compositions and formulations thereof, and methods for modulating the A22B adenosine receptor for treatment of A2B adenosine receptor mediated diseases or conditions.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor.

Abstract: Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor.

Abstract: A communication device and methods for operating the same. One communication device includes a memory storing a software application, an electronic processor, a mechanical interface receiving a first user input, and a touch screen receiving a second user input. The touch screen is also configured to display an output generated by the software application. The electronic processor is configured to execute a software application stored in the memory, determine when the second user input is received simultaneously with the first user input, perform a first action based on the first user input when the second user input is not received simultaneously with the first user input, the first action being unrelated to operation of the software application, and perform a second action based on the first user input when the second user input is received simultaneously with the first user input, the second action relating to the operation of the software application.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: A communication device and methods for operating the same. One communication device includes a memory storing a software application, an electronic processor, a mechanical interface receiving a first user input, and a touch screen receiving a second user input. The touch screen is also configured to display an output generated by the software application. The electronic processor is configured to execute a software application stored in the memory, determine when the second user input is received simultaneously with the first user input, perform a first action based on the first user input when the second user input is not received simultaneously with the first user input, the first action being unrelated to operation of the software application, and perform a second action based on the first user input when the second user input is received simultaneously with the first user input, the second action relating to the operation of the software application.

Abstract: Techniques are provided that may be generally associated with content and media, such as digital photos or videos from events. Techniques are provided, for example, relating to creating, identifying, identifying one or more individuals in, selecting, characterizing, obtaining, providing, storing, organizing or searching such content or media or elements thereof. Digital photos or video, for example, may be taken prior to or after an event, in which RFID or barcode technology is used in obtaining metadata associated with the images that may include identification information regarding individuals in the photos. Facial recognition or appearance recognition technology may be used in identifying individuals in digital photos or video taken at events, and may be made available to individuals or accounts. Techniques are also provided that include use of RFID technology, and may include enhancements thereto, to identify individuals in digital photos or videos taken at events from RFID tags.